Comparative study of low doses of rosuvastatin and atorvastatin on lipid and glycemic control in patients with metabolic syndrome and hypercholesterolemia

Jong-Seon Park, Young-Jo Kim, Ji-Yong Choi, Yoon-Nyun Kim, Teck-Jong Hong, Dong-Soo Kim, Ki-Young Kim, Myung-Ho Jeong, Jei-Keon Chae, Seok-Kyu Oh, In-Whan Seong, Jong-Seon Park, Young-Jo Kim, Ji-Yong Choi, Yoon-Nyun Kim, Teck-Jong Hong, Dong-Soo Kim, Ki-Young Kim, Myung-Ho Jeong, Jei-Keon Chae, Seok-Kyu Oh, In-Whan Seong

Abstract

Background/aims: This multicenter, open-labeled, randomized trial was performed to compare the effects of rosuvastatin 10 mg and atorvastatin 10 mg on lipid and glycemic control in Korean patients with nondiabetic metabolic syndrome.

Methods: In total, 351 patients who met the modified National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) criteria for metabolic syndrome with low-density lipoprotein cholesterol (LDL-C) levels > or = 130 mg/dL were randomized to receive either rosuvastatin 10 mg (n = 173) or atorvastatin 10 mg (n = 178) for over 6 weeks.

Results: After 6 weeks of treatment, greater reductions in total cholesterol (- 35.94 +/- 11.38 vs. - 30.07 +/- 10.46%, p < 0.001), LDL-C (48.04 +/- 14.45 vs. 39.52 +/- 14.42%, p < 0.001), non-high-density lipoprotein cholesterol (- 42.93 +/- 13.15 vs. - 35.52 +/- 11.76%, p < 0.001), and apolipoprotein-B (- 38.7 +/- 18.85 vs. - 32.57 +/- 17.56%, p = 0.002) levels were observed in the rosuvastatin group as compared to the atorvastatin group. Overall, the percentage of patients attaining the NCEP ATP III goal was higher with rosuvastatin as compared to atorvastatin (87.64 vs. 69.88%, p < 0.001). Changes in glucose and insulin levels, and homeostasis model assessment of insulin resistance index were not significantly different between the two groups. The safety and tolerability of the two agents were similar.

Conclusions: Rosuvastatin 10 mg was more effective than atorvastatin 10 mg in achieving NCEP ATP III LDL-C goals in patients with nondiabetic metabolic syndrome, especially in those with lower NCEP ATP III target level goals.

Keywords: Atorvastatin; Hypercholesterolemia; Metabolic syndrome X; Rosuvastatin.

Conflict of interest statement

No potential conflict of interest relevant to this article was reported.

Figures

Figure 1
Figure 1
Trial design. LDL, low-density lipoprotein; HDL, high-density lipoprotein.
Figure 2
Figure 2
Percent change of lipid and apolipoprotein after treatment for 6 weeks. LDL-C, low-density lipoprotein cholesterol; Total-C, total cholesterol; HDL-C, high-density lipoprotein cholesterol; Apo, apolipoprotein.
Figure 3
Figure 3
Proportions of patients reaching different Adult Treatment Panel III, low-density lipoprotein cholesterol (LDL-C) level goals at 6 weeks after treatment. aProportion of patients reaching LDL-C level goal < 100, 130 or 160 mg/dL depending on risk category at baseline.

References

    1. Brewer HB., Jr New features of the National Cholesterol Education Program Adult Treatment Panel III lipid-lowering guidelines. Clin Cardiol. 2003;26(4 Suppl 3):III19–III24.
    1. Kwon HS, Park YM, Lee HJ, et al. Prevalence and clinical characteristics of the metabolic syndrome in middle-aged Korean adults. Korean J Intern Med. 2005;20:310–316.
    1. Kim YK. Impact of the metabolic syndrome and its components on pulse wave velocity. Korean J Intern Med. 2006;21:109–115.
    1. Boden WE. Therapeutic implications of recent ATP III guidelines and the important role of combination therapy in total dyslipidemia management. Curr Opin Cardiol. 2003;18:278–285.
    1. Yood MU, McCarthy BD, Kempf J, et al. Racial differences in reaching target low-density lipoprotein goal among individuals treated with prescription statin therapy. Am Heart J. 2006;152:777–784.
    1. Leibovitz E, Harats D, Gavish D. Efficacy of atorvastatin in treating high risk patients to reach low density lipoprotein-cholesterol goals: the Treat to Target (TTT-Israel) Study. Isr Med Assoc J. 2002;4:407–410.
    1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA. 2001;285:2486–2497.
    1. McKenney JM, Jones PH, Adamczyk MA, et al. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr Med Res Opin. 2003;19:689–698.
    1. Clearfield MB, Amerena J, Bassand JP, et al. Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia: prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR) Trials. 2006;7:35.
    1. Ferdinand KC, Clark LT, Watson KE, et al. Comparison of efficacy and safety of rosuvastatin versus atorvastatin in African-American patients in a six-week trial. Am J Cardiol. 2006;97:229–235.
    1. Choi SH, Ahn CW, Cha BS, et al. The prevalence of the metabolic syndrome in Korean adults: comparison of WHO and NCEP criteria. Yonsei Med J. 2005;46:198–205.
    1. Deedwania PC, Hunninghake DB, Bays HE, et al. Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome. Am J Cardiol. 2005;95:360–366.
    1. Dekker JM, Girman C, Rhodes T, et al. Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. Circulation. 2005;112:666–673.
    1. Davidson MH. Differences between clinical trial efficacy and realworld effectiveness. Am J Manag Care. 2006;12(15 Suppl):S405–S411.
    1. Stalenhoef AF, Ballantyne CM, Sarti C, et al. A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study. Eur Heart J. 2005;26:2664–2672.
    1. Deedwania PC, Gupta M, Stein M, Ycas J, Gold A. Comparison of rosuvastatin versus atorvastatin in South-Asian patients at risk of coronary heart disease (from the IRIS Trial) Am J Cardiol. 2007;99:1538–1543.
    1. Grundy SM, Hansen B, Smith SC, Jr, Cleeman JI, Kahn RA. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation. 2004;109:551–556.
    1. Pivatto I, Bustos P, Amigo H, Acosta AM, Arteaga A. Association between proinsulin, insulin, proinsulin/insulin ratio, and insulin resistance status with the metabolic syndrome. Arq Bras Endocrinol Metabol. 2007;51:1128–1133.
    1. Naples M, Federico LM, Xu E, Nelken J, Adeli K. Effect of rosuvastatin on insulin sensitivity in an animal model of insulin resistance: evidence for statin-induced hepatic insulin sensitization. Atherosclerosis. 2008;198:94–103.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する